Moderna and Merck are moving from trial success toward regulatory submission after a large Phase 3 trial in melanoma showed their personalized mRNA cancer vaccine, known chemically as intismeran autogene, significantly delayed both cancer recurrence and the development of metastatic disease. The companies are preparing to file the vaccine for approval and discussed next steps publicly at the 2026 STAT Summit in Boston.
The vaccine was tested in combination with Merck’s checkpoint inhibitor Keytruda, a therapy that has been evaluated across thousands of trials over the last 15 years. Because Keytruda performs better in tumors with high mutational burden — so-called hot tumors — Merck and Moderna have initially concentrated on clinical settings where checkpoint inhibitors are already effective.
The vaccine is a personalized mRNA product created by sequencing an individual patient’s tumor and running those data through an algorithm the companies use to pick up to 34 mutant proteins. The selected mutant proteins are encoded by mRNA so the patient’s immune system can be trained to recognize those aberrant proteins as targets.
Moderna and Merck acknowledged that the selection algorithm is imperfect. At the STAT Summit, Moderna President Stephen Hoge said the companies now have immune-system data from several thousand people in their Phase 3 program and plan to analyze that information to refine their software and potentially improve target selection.
Merck and Moderna have focused early development on adjuvant settings — treatment given after surgical tumor removal — because those are where checkpoint inhibitors such as Keytruda have shown benefit. According to their remarks at the summit, ongoing trials include adjuvant studies in lung, kidney, and bladder cancer.
The companies have also launched small adjuvant trials in pancreatic and gastric cancer to test feasibility in tumor types where outcomes have traditionally been poorer. Merck R&D chief Dean Li said the team has intentionally prioritized where to explore next rather than immediately pursuing all possible indications.
Li suggested other possible avenues under consideration, including testing the vaccine in tumors where Keytruda has failed but another form of immunotherapy showed activity, and using the vaccine as a standalone therapy in very early-stage tumors. He also floated using the vaccine in patients whose metastatic disease has already been reduced by other treatments — though specific trial designs and timelines were not reported in the source.
At the STAT Summit, both executives emphasized a deliberate strategy. Stephen Hoge said, “We have a lot of exploring to do and need to prioritize where we explore.” Dean Li contrasted Merck and Moderna’s approach with other companies that have targeted cold or metastatic tumors earlier, indicating that their current focus leverages experience with checkpoint inhibitors.
Li added that Merck and Moderna would be ready to move quickly if other companies produced positive data, saying that the pair would not pivot slowly in response to competitors. The comment appeared to reference other companies in the mRNA cancer vaccine field that have reported mixed results.
One patient who took part in an early trial, Gary Keblish, shared his experience via video at the summit. Keblish was diagnosed with melanoma in 2019, had his tumor surgically removed, and enrolled in the Merck–Moderna personalized vaccine trial. He described the emotional and physical turbulence of the journey and said he remains at work as a teacher. His case was presented as an example of the vaccine’s impact on individual patients in the context of the Phase 3 results.
The Phase 3 finding represents a significant moment for the cancer vaccine field, which has for decades aimed to produce effective, personalized immunotherapies. Merck and Moderna’s program combines the personalized mRNA approach with an established checkpoint inhibitor, rather than relying solely on the vaccine to drive antitumor effects.
Beyond indications and trial sites, the companies will continue to refine the core technology. The current process depends on tumor sequencing plus an algorithm to choose antigenic targets. Moderna’s Hoge highlighted the value of having extensive immune-system data from the Phase 3 program — several thousand participants — as a resource to improve that algorithm and better understand which targets best stimulate protective immune responses.
The source did not report detailed plans, timelines, or specific algorithm changes the companies intend to pursue, nor did it provide numeric efficacy data from the Phase 3 trial beyond the statement that it significantly delayed recurrence and metastatic disease.
The immediate next step reported by the companies is preparing a regulatory filing based on the Phase 3 melanoma results. Parallel to that effort, they are running and initiating trials in multiple adjuvant indications (lung, kidney, bladder) and conducting small tests in pancreatic and gastric cancers.
Longer-term questions remain that the source did not answer: how broadly the vaccine will work outside melanoma, how much the antigen-selection algorithm can be improved, whether the vaccine will provide benefit as a standalone therapy in early disease, and the precise regulatory and commercialization timelines. Merck and Moderna have signaled they will be selective about where to expand and will use their large clinical dataset to guide decisions.
For now, the Phase 3 outcome and the companies’ planned filing mark a key inflection point for personalized cancer vaccines, while underscoring that substantial clinical and technical work still lies ahead.
Sources cited in this report: STAT Summit presentations and companies’ public announcement of Phase 3 results in August 2026 as reported by STAT News.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.